Dr. Muhammad Naeem Abbas, Dr. Zain-ul-abideen, Dr. Iqra Khan
Introduction: Asthma is an inflammatory chronic disease of multifactorial aetiology, including allergic asthma, which is characterized by eosinophilic airway inflammation, often sustained by allergic sensitization. IgE plays a central role in the pathogenesis of allergic diseases. After sensitization, atopic patients respond to allergen exposure through a number of IgE-dependent mechanisms. Objectives of the study: The main objective of the study is to analyze the use of intravenous and subcutaneous monoclonal antibodies in the treatment of asthma. Methodology of the study: This cross sectional study was conducted in Allied Hospital Faisalabad during March 2019 to July 2019. Male or female allergic asthmatics aged 12 to 75 years who were symptomatic despite treatment with ICSs were eligible if they met the following criteria: duration of asthma, ≥1 year; positive immediate responses on skin prick testing to at least 1 common allergen. Results: Additionally, health-related quality of life was measured using SGRQ. At Week 24, there was a statistically significant improvement in the mean SGRQ score for mepolizumab compared with placebo: -5.8 (95% CI: -10.6,-1.0; P=0.019). Conclusion: It is concluded that omalizumab is effective and safe in patients with severe allergic asthma who experience poor disease control or exacerbations despite recommended therapy.